Abstract
The aim of this study was to evaluate effect of c-KIT mutations on RUNX1/RUNX1T1 fusion transcript expression in patients with t(8;21)-positive AML. Fifty patients diagnosed with t(8;21)-positive AML for recent 10 years were enrolled. Patients with c-KIT mutations tended to achieve a greater than 3-log reduction in RUNX1/RUNX1T1 fusion transcript expression less frequently than patients without mutations from 6 to 12 months of follow-up. They have difficulties to obtain molecular complete remission and experience molecular relapse more frequently and rapidly than those without mutations. These results support poor prognostic impact of c-KIT mutations in t(8;21)-positive AML.
Copyright © 2013 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Child
-
Child, Preschool
-
Chromosomes, Human, Pair 21 / genetics*
-
Chromosomes, Human, Pair 8 / genetics*
-
Core Binding Factor Alpha 2 Subunit / genetics*
-
DNA, Neoplasm / genetics
-
Female
-
Follow-Up Studies
-
Humans
-
Leukemia, Myeloid, Acute / genetics*
-
Leukemia, Myeloid, Acute / mortality
-
Leukemia, Myeloid, Acute / therapy
-
Male
-
Middle Aged
-
Mutation / genetics*
-
Neoplasm Recurrence, Local / genetics*
-
Neoplasm Recurrence, Local / mortality
-
Neoplasm Recurrence, Local / therapy
-
Oncogene Proteins, Fusion / genetics*
-
Prognosis
-
Proto-Oncogene Proteins c-kit / genetics*
-
RUNX1 Translocation Partner 1 Protein
-
Real-Time Polymerase Chain Reaction
-
Retrospective Studies
-
Survival Rate
-
Translocation, Genetic / genetics*
-
Young Adult
Substances
-
AML1-ETO fusion protein, human
-
Core Binding Factor Alpha 2 Subunit
-
DNA, Neoplasm
-
Oncogene Proteins, Fusion
-
RUNX1 Translocation Partner 1 Protein
-
Proto-Oncogene Proteins c-kit